Mirikizumab (Omvoh)

Indications

Adults with moderate-to-severe active UC who: have not responded to an anti-TNF; have stopped responding to an anti-TNF; have tried an anti-TNF but had to stop it because of side effects; and/or are not suitable for treatment with an anti‑TNF.

Contraindications

| Potential side effects: Nose and throat infection; joint pain; headache; opportunistic infection

Preparations Available

Intravenous infusion for induction; subcutaneous injection for maintenance

Quantity

Dose: Induction up to week 8: 300mg every 4 weeks. Maintenance beyond week 8: 200mg every 4 weeks.

Sizes Available

300mg vial for injection, £2,056.56

Price

300mg vial for injection, £2,056.56

More on: Biologics